LSKL Peptide Attenuates Ovarian Oxidative Stress and Apoptosis in PCOS Models via THBS1/PI3K/AKT Pathway

Study Background and Research Question

Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder affecting up to 18% of women of reproductive age. Characterized by ovulatory dysfunction, hyperandrogenism, and polycystic ovarian morphology, PCOS is increasingly recognized as a condition rooted in chronic inflammation and oxidative stress. Granulosa cell (GC) apoptosis and redox imbalance within the ovarian microenvironment contribute to the pathophysiology, with downstream effects on fertility and metabolic health. Recent attention has focused on the extracellular matrix glycoprotein thrombospondin-1 (THBS1), which is upregulated in PCOS and implicated in angiogenesis, fibrosis, and cellular signaling disruptions. However, the therapeutic potential of targeting THBS1 remains underexplored, particularly in the context of oxidative stress-driven ovarian injury.

Key Innovation from the Reference Study

The study by Zhang et al. (2026) makes a significant advance by systematically investigating the impact of Leu-Ser-Lys-Leu-NH2 (LSKL), a peptide inhibitor of THBS1, on DHEA-induced PCOS models in rats and isolated granulosa cells. The defining innovation is the elucidation of a protective mechanism: LSKL disrupts THBS1 activity, thereby activating the PI3K/AKT pathway, reducing oxidative stress, and preventing GC apoptosis. This mechanistic link between THBS1 inhibition, redox homeostasis, and cell survival in ovarian tissue positions LSKL as a promising candidate for mitigating PCOS-related dysfunction.

Methods and Experimental Design Insights

The research employed a multi-tiered experimental approach:

• PCOS was modeled by administering dehydroepiandrosterone (DHEA) to rats and cultured granulosa cells for 21 days, recapitulating key pathological features.
• LSKL peptide was administered post-induction to evaluate therapeutic effects.
• Molecular docking assessed direct interactions between LSKL and THBS1, confirming high-affinity binding.
• Cell viability and apoptosis were quantified via CCK8 assays and flow cytometry, while intracellular reactive oxygen species (ROS) levels were measured using established fluorescence-based techniques.
• In vivo analyses included monitoring estrous cycles, ovarian histopathology, serum hormone quantification (LH, FSH, testosterone, estradiol), and immunoblotting of PI3K/AKT and apoptosis-related proteins.

This design integrates both molecular and physiological endpoints, strengthening the validity of observed mechanistic effects.

Core Findings and Why They Matter

Several pivotal findings emerged from the study:

• Direct Inhibition of THBS1: LSKL binds THBS1 with high affinity, as demonstrated by molecular docking studies.
• Reduction of Oxidative Stress: In DHEA-induced granulosa cells, LSKL markedly decreased ROS accumulation and rescued cell viability.
• Suppression of Apoptosis: LSKL treatment significantly inhibited apoptotic markers, indicating protection against GC loss.
• Activation of PI3K/AKT Pathway: Both in vitro and in vivo, LSKL restored PI3K/AKT signaling, which is known to promote cell survival and counteract oxidative damage.
• Improved Ovarian Physiology: In rats, LSKL reversed DHEA-induced ovarian injury, normalized estrous cycles, improved follicular morphology, and restored hormonal balance.

Collectively, these results identify THBS1 as a crucial driver of PCOS-related ovarian dysfunction and demonstrate that LSKL can restore redox balance and cellular integrity through regulation of the PI3K/AKT pathway. Importantly, this work links a specific ECM protein to the intracellular redox environment and apoptotic signaling in the context of PCOS, opening avenues for targeted intervention.

Comparison with Existing Internal Articles

Several internal resources provide context for the methodological and translational aspects of this work. For example, "LSKL Peptide Reduces Ovarian Oxidative Stress via THBS1/PI3K/AKT Axis" highlights the same mechanism, reinforcing the reference study’s conclusions. In parallel, articles such as "2,7-Dichlorodihydrofluorescein Diacetate for ROS Assays in Inflammation" and "2,7-Dichlorodihydrofluorescein Diacetate for Cellular ROS Detection" focus on the technical specifics of intracellular ROS quantification using 2,7-Dichlorodihydrofluorescein diacetate (DCFH-DA). These resources detail how DCFH-DA enables sensitive, reproducible detection of oxidative stress in live-cell assays—a crucial methodological pillar for studies like that of Zhang et al.

Furthermore, "Strategic ROS Assays: DCFH-DA and Translational Redox Biology" bridges these assay tools to broader translational research, including PCOS and mitochondrial dysfunction, providing protocol guidance relevant to the reference study. Collectively, these articles underscore the importance of robust ROS detection methods in elucidating disease mechanisms and validating therapeutic interventions.

Limitations and Transferability

While the study by Zhang et al. provides compelling evidence for the therapeutic targeting of THBS1 in PCOS, several limitations warrant consideration:

• The models used—DHEA-induced PCOS in rats and isolated granulosa cells—recapitulate many aspects of human pathology but may not fully represent the heterogeneity seen in clinical PCOS.
• Although LSKL’s efficacy was demonstrated at the cellular and organ level, its long-term safety, pharmacokinetics, and potential off-target effects require further investigation.
• ROS measurements using DCFH-DA or similar fluorescent probes, while sensitive, can be susceptible to artifacts and lack absolute specificity for particular ROS species, necessitating complementary validation approaches.

Therefore, while the mechanistic findings are robust and provide a foundation for future preclinical or translational work, direct application to clinical therapeutics will require extensive validation in human tissues and more diverse PCOS models.

Protocol Parameters

• DHEA induction of PCOS: 21 days of DHEA administration in rats or granulosa cell cultures to induce PCOS-like pathology before intervention.
• LSKL treatment: Administered after PCOS induction; dosage and timing should mirror published protocols for effective THBS1 inhibition.
• ROS quantification: Use of 2,7-Dichlorodihydrofluorescein diacetate (DCFH-DA) at micromolar concentrations as a cell-permeable fluorogenic probe for intracellular reactive oxygen species detection, with measurements by fluorescence microscopy, flow cytometry, or microplate assays.
• Assessment endpoints: Include cell viability (CCK8), apoptosis (flow cytometry, immunoblotting), hormonal profiling, and ovarian histopathology to comprehensively evaluate intervention effects.

Research Support Resources

For investigators seeking to replicate or extend these findings, robust tools for intracellular ROS detection are critical. 2,7-Dichlorodihydrofluorescein diacetate (DCFH-DA, SKU C3890) is widely utilized as a cell-permeable ROS indicator in fluorescence microscopy ROS detection, flow cytometry ROS assay, and plate-based oxidative stress assay workflows. As detailed in the product information and in recent workflow analyses, careful protocol design and appropriate controls are recommended to ensure assay accuracy and specificity. APExBIO provides DCFH-DA reagents suitable for these applications, supporting redox biology research in PCOS, inflammation, and related disease models.